Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Ascentage Pharma Group International

Healthcare US AAPG

17.2USD
-1.08(5.91%)

Last update at 2026-06-05T20:00:00Z

Day Range

17.1017.62
LowHigh

52 Week Range

19.1148.45
LowHigh

Fundamentals

  • Previous Close 18.28
  • Market Cap2522.70M
  • Volume13258
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1132.25203M
  • Revenue TTM574.12M
  • Revenue Per Share TTM6.45
  • Gross Profit TTM 525.18M
  • Diluted EPS TTM-2.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1202.37110M -395.25500M -932.86200M -887.17200M -832.24900M
Minority interest - 0.25M 0.07M 0.00000M -
Net income -1208.90997M -405.43300M -925.63700M -882.92400M -782.42400M
Selling general administrative - 187.12M 181.08M 170.59M 143.51M
Selling and marketing expenses - 196.00M 195.39M 157.42M 47.75M
Gross profit 426.75M 951.57M 191.44M 187.71M 24.58M
Reconciled depreciation - 93.17M 93.19M 62.91M 28.33M
Ebit -1179.16116M -330.80000M -836.80500M -834.38700M -815.51800M
Ebitda -1095.03730M -237.63100M -743.61000M -786.96600M -798.33500M
Depreciation and amortization 84.12M 93.17M 93.19M 47.42M 17.18M
Non operating income net other - - - - -
Operating income -1179.16117M -369.73000M -872.63600M -849.81000M -869.83500M
Other operating expenses 1737.64M 1350.38M 1094.62M 1059.52M 961.08M
Interest expense 52.60M 64.45M 96.06M 52.78M 16.73M
Tax provision - 10.43M -7.15000M -4.24800M -49.82500M
Interest income - 37.84M 32.41M 9.73M 7.11M
Net interest income - -26.61500M -63.64800M -43.05800M -9.62500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 6.75M 10.43M -7.15000M -4.24800M -49.82500M
Total revenue 558.48M 980.65M 221.98M 209.71M 27.91M
Total operating expenses 1605.91M 1321.30M 1064.08M 1037.52M 894.42M
Cost of revenue 131.73M 29.09M 30.54M 22.00M 3.33M
Total other income expense net -23.20994M -25.52500M -60.22600M -37.36200M 37.59M
Discontinued operations - - - - -
Net income from continuing ops - -405.68000M -925.71200M -882.92400M -782.42400M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3966.10M 2617.81M 2500.39M 2830.26M 2940.06M
Intangible assets 65.98M 76.00M 85.45M 84.30M 60.41M
Earning assets - - - - -
Other current assets 192.65M 131.91M 95.17M 89.91M 120.34M
Total liab 2631.04M 2343.65M 2429.76M 2421.60M 1705.32M
Total stockholder equity 1325.31M 264.19M 60.42M 408.66M 1234.74M
Deferred long term liab - - - - -
Other current liab 276.84M 231.87M 198.53M 235.68M 237.52M
Common stock 0.26M 0.21M 0.20M 0.18M 0.18M
Capital stock - 0.21M 0.20M 0.18M 0.18M
Retained earnings - -5770.55500M -5365.12200M -4439.48500M -3556.56100M
Other liab - - - - -
Good will 24.71M 24.69M 24.69M 24.69M 24.69M
Other assets - - - - -
Cash 2471.66M 1236.58M 1069.30M 1475.64M 1706.89M
Cash and equivalents - - - - -
Total current liabilities 1644.42M 1166.61M 934.17M 881.15M 361.11M
Current deferred revenue 37.51M 54.09M 38.41M 24.35M -
Net debt -490.67827M 431.92M 726.30M 317.09M -622.59600M
Short term debt 1223.26M 779.06M 616.40M 518.38M 49.45M
Short long term debt - 769.62M 606.65M 510.31M 39.80M
Short long term debt total 1980.98M 1668.50M 1795.60M 1792.73M 1084.29M
Other stockholder equity -2.96288M 6545.12M 5929.80M 5366.48M 5342.07M
Property plant equipment - - - - -
Total current assets 2946.05M 1474.16M 1344.18M 1636.49M 1885.28M
Long term investments - 33.86M 18.95M 18.53M 27.84M
Net tangible assets - - - - -
Short term investments - 5.37M 4.41M 18.70M -
Net receivables 253.10M 99.07M 163.54M 61.49M 54.13M
Long term debt - 868.64M 1166.27M 1265.20M 1026.59M
Inventory 28.64M 6.60M 16.17M 9.45M 3.93M
Accounts payable 106.81M 91.97M 72.44M 95.56M 70.86M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1328.01M -510.58600M -504.46100M -518.51400M -550.94900M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 30.74M 59.00M 10.05M 361.93M 35.88M
Deferred long term asset charges - - - - -
Non current assets total 1020.05M 1143.65M 1156.21M 1193.77M 1054.78M
Capital lease obligations - 30.23M 22.68M 17.22M 17.90M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -362.03500M 21.92M -384.61200M -466.52200M -107.36700M
Change to liabilities - - - - -
Total cashflows from investing activities -362.03500M 21.92M -384.61200M -466.52200M -107.36700M
Net borrowings -145.34000M -13.35700M 695.87M 539.50M -
Total cash from financing activities 314.77M 368.75M 619.27M 1781.39M 1040.00M
Change to operating activities - - - - -
Net income -395.25500M -932.86200M -887.17200M -832.24900M -675.44800M
Change in cash -144.94800M -307.59100M -361.24700M 686.91M 280.99M
Begin period cash flow 1038.05M 1345.64M 1706.89M 1019.98M 738.99M
End period cash flow 893.10M 1038.05M 1345.64M 1706.89M 1019.98M
Total cash from operating activities -111.35700M -726.07700M -653.91500M -604.67900M -609.95600M
Issuance of capital stock 533.94M 470.08M 0.02M 1300.64M 634.22M
Depreciation 93.17M 93.19M 62.91M 28.33M 27.42M
Other cashflows from investing activities -312.23000M 88.03M -31.32400M -0.87900M -1.55500M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M -
Change to inventory 9.57M -6.71900M -5.51800M -3.93000M 0.00000M
Change to account receivables 62.75M -91.53700M -0.38800M -53.96800M -
Sale purchase of stock 0.00000M -5.92300M -26.77600M -25.87400M 0.00000M
Other cashflows from financing activities -73.83300M -82.05000M -49.83000M -41.97100M -27.01900M
Change to netincome - - - - -
Capital expenditures 24.29M 56.84M 236.96M 436.63M 251.48M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 110.97M -9.14600M 104.41M -74.91100M -55.25100M
Stock based compensation 20.92M 31.50M 22.11M 46.97M 74.03M
Other non cash items 58.84M 91.23M 43.82M 227.18M 19.29M
Free cash flow -135.64600M -782.92100M -890.87800M -1041.30800M -861.43200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x)
AAPG
Ascentage Pharma Group International		 -1.08 5.91% 17.20 - - 4.39 12.66 28.27
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Ascentage Pharma Group International

Suzhou Industrial Park, Suzhou, China, 215000

Key Executives

Name Title Year Born
Dr. Dajun Yang M.D., Ph.D. Co-Founder, Chairman & CEO 1963
Dr. Shaomeng Wang Ph.D. Co-Founder, Chief Scientific Advisor & Non-Executive Director 1965
Dr. Ming Guo Co-Founder 1958
Dr. Veet Misra Chief Financial Officer NA
Yuly Chen Senior Director of Investor Relations NA
Mr. Thomas Joseph Knapp J.D. Senior VP & General Counsel 1953
Dr. Yifan Zhai M.D., Ph.D. Chief Medical Officer 1963
Dr. Chongdong Fu Senior VP & Head of CMC NA
Mr. Jin Cao Head of Finance 1986
Ms. Hoi Yan Leung Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions